Adjunctive agents like aspirin (which inhibits IκB kinase to some extent) or corticosteroids (which broadly suppress NF-κB activity) have already shown benefits in reducing TB inflammation and IRIS severity, respectively. The gene discussed is NFKB1; the disease is tuberculosis.